secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0000950170-24-107614
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health receives IRB approval from Feinstein Institutes for ncVNS optimization study
--------------------------------------------------------------------------------

- Received IRB approval from Feinstein Institutes for clinical optimization study of ncVNS; enrollment to commence.
- Study will optimize stimulation parameters and electrode positioning using physiological measurements.
- Data will guide selection of clinical populations and design of future disease-specific trials.
- Collaboration with Fletcher Spaght to identify high-unmet-need clinical applications for ncVNS.
- Global VNS market valued at $8.59B (2021), projected $21.3B by 2030, CAGR 10.6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/0000950170-24-107614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024107614/tivc-20240918.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer